** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to "market perform" from "outperform," cuts PT to $4 from $5
** Cites "uncertainties" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine
** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared
** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate
** Six of seven analysts rate CMPX stock "buy" or higher and one "hold"; their median PT is $7.50 - LSEG
** As of last close, CMPX stock has risen 1.9% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。